Source-grounded facts extracted from Hepion Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hepion Pharmaceuticals, Inc. shareholders approved Approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. at the 2026-06-17 meeting.
“To approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. Votes For Votes Against Votes Abstained Broker Non-Vote 13,442,072 208,879 1,751 4,816,704”
Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. at the 2026-06-17 meeting.
“To ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 18,128,998 116,985 223,423 0”
Hepion Pharmaceuticals, Inc. shareholders approved Election of five director nominees: Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore at the 2026-06-17 meeting.
“To elect the five (5) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified consisting of Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore. Name Votes For Withhold Broker Non-Vote Gary Stetz 13,498,755 153,947 4,816,704 Vincent LoPriore 13,492,507 160,195 4,816,704 Michael Purcell 13,186,912 465,790 4,816,704 Sireesh Appajosyula 13,503,469 149,233 4,816,704 Chase LoPriore 13,492,110 160,592 4,816,704”
Hepion Pharmaceuticals, Inc. issued 17,500,000 shares of common stock of common stock to certain accredited investors for $0.04 per share for gross proceeds of $700,000.
“On April 21, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “Offering”), an aggregate offering of 17,500,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an offering price of $0.04 per share for gross proceeds of $700,000.”
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with certain accredited investors valued at $700,000 (effective 2026-04-21).
“On April 21, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “Offering”), an aggregate offering of 17,500,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an offering price of $0.04 per share for gross proceeds of $700,000.”
Hepion Pharmaceuticals, Inc. entered into intellectual property license agreement with Cirna Diagnostics, LLC valued at upfront payment of $50,000 as well as certain patent expenses, up to $2,350,000 in milestone payment (effective 2026-02-25).
“On February 25, 2026, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an intellectual property license agreement with Cirna Diagnostics, LLC (“ Cirna ”) pursuant to which the Company licensed certain liver disease diagnostic assets from Cirna.”
Kaouthar Lbiati was appointed as Interim Chief Executive Officer at Hepion Pharmaceuticals, Inc..
“On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.”
Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(2), 5101).
“May 9, 2025, Hepion Pharmaceuticals, Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public s”
Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5101).
“May 9, 2025, Hepion Pharmaceuticals, Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public s”
Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other.
“April 15, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the Staff believes that the Company is a “public shell” and that the continued listing of its securities is no longer warranted. The Staff stated that this serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. The Notice is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in rendering a determination regarding the Compa”
Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).
“March 18, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “ Common Stock ”), for the last 10 consecutive business days, had closed below $0.10 per share and, as a result, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Na”
Hepion Pharmaceuticals, Inc.: Amended certificate of incorporation to effect a one-for-fifty reverse stock split (effective 2025-03-17).
“the Company filed the Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split became effective in accordance with the terms of the Amendment at 4:01 pm Eastern Time on March 17, 2025 (the “Effective Time”).”
Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.
“January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not held an annual meeting of shareholders within twelve months of the Company’s fiscal year end (the “Listing Rule”), the Company no longer complies with the Listing Rule for continued listing. The Notice has no effect at this time on the Common Stock, which continues to trade on the Nasdaq Capital Market under the symbol “HEPA.” Under the Listing Rule, the Company has 45 days to”
Hepion Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding shareholders.
“January 14, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that since the Company had not”
John Brancaccio was appointed as interim Chief Executive Officer and interim Chief Financial Officer at Hepion Pharmaceuticals, Inc..
“On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.”
John Cavan departed as interim Chief Executive Officer and Chief Financial Officer at Hepion Pharmaceuticals, Inc..
“On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.”
Michael Purcell was appointed as Director at Hepion Pharmaceuticals, Inc..
“On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) appointed Michael Purcell as a director of the Company.”
John Brancaccio was appointed as Chairman at Hepion Pharmaceuticals, Inc..
“Dr. Jacob was Chairman of the Company and the Board of Directors appointed John Brancaccio as Chairman.”
Gary Jacob resigned as Chairman of the Board at Hepion Pharmaceuticals, Inc..
“On February 20, 2024, Dr. Gary Jacob resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) for personal reasons.”
Anand Reddi resigned as Director at Hepion Pharmaceuticals, Inc..
“On February 7, 2024, Anand Reddi resigned from the Board of Directors of Hepion Pharmaceuticals, Inc.”
Hepion Pharmaceuticals, Inc. engaged Grassi Advisors as its auditor.
“approved the engagement of Grassi Advisors (“Grassi”) as the Company’s independent registered public accounting firm”
Hepion Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its auditor.
“the audit committee of the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the dismissal of BDO USA, P.C. (“BDO”) as the Company’s independent registered public accounting firm”
Dr. Peter Wijngaard resigned as Director at Hepion Pharmaceuticals, Inc..
“Dr. Peter Wijngaard resigned from the Board of Directors of the Company.”
John Cavan was appointed as interim Chief Executive Officer at Hepion Pharmaceuticals, Inc..
“the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.”
Dr. Robert Foster resigned as Chief Executive Officer at Hepion Pharmaceuticals, Inc..
“Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately.”
Hepion Pharmaceuticals, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.0 million (effective 2023-09-28).
“On September 28, 2023, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor, in a registered direct offering (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $5.10 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 580,393 shares of the Company’s Common Stock at an exercise price of $0.0001 per share at an offering price of $5.09 per share.”
Stephen Harrison was appointed as Consultant Medical Director at Hepion Pharmaceuticals, Inc..
“On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.”
Todd Hobbs resigned as Chief Medical Officer at Hepion Pharmaceuticals, Inc..
“On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.”
Hepion Pharmaceuticals, Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at up to $24,000,000 (effective 2023-07-21).
“On July 21, 2023, Hepion Pharmaceuticals, Inc. (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. as sales agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $24,000,000 (the “Shares”).”
Hepion Pharmaceuticals, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company's named executive officers at the 2023-06-22 meeting.
“To approve, on an advisory basis, the compensation of the Company’s named executive officers, referred to as “say-on-pay.”
Hepion Pharmaceuticals, Inc. shareholders approved Approve the Company's 2023 Omnibus Equity Incentive Plan at the 2023-06-22 meeting.
“To approve the Company’s 2023 Omnibus Equity Incentive Plan.”
Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of BDO USA, LLP as the Company's independent auditors for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
“To ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.”
Hepion Pharmaceuticals, Inc. shareholders approved Election of seven directors at the 2023-06-22 meeting.
“To elect the seven (7) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified including Gary S. Jacob, Robert Foster, John P. Brancaccio, Timothy Block, Peter Wijngaard, Anand Reddi and Kaouthar Lbiati.”
Hepion Pharmaceuticals, Inc.: Company filed a Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock, effective 4:01 p.m. ET on May 10, 2023, as previously approved by stockholders and board (effective 2023-05-10).
“On May 10, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”
Hepion Pharmaceuticals, Inc. shareholders approved Adoption and approval of an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio ranging from 1:2 to 1:20, with the exact ratio determined by the Board at the 2022-12-15 meeting.
“The proposal to adopt and approve an amendment to the Charter to effect a reverse stock split of the Company’s issued and outstanding shares of Common Stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-twenty (1:20), at any time prior to the one-year anniversary date of the Special Meeting, with the exact ratio to be determined by the Board was approved by a majority of the voting power of the outstanding shares of Common Stock, Series A Preferred Stock Series F Preferred Stock and Series G Preferred Stock entitled to vote on the proposal, based upon the following votes: Votes For Votes Against Votes Abstained Broker Non-Vote 6,757,528,739 3,262,017,173 38,856,945 0”
Hepion Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at gross proceeds of $20 million (effective 2022-11-04).
“On November 4, 2022, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), 1,900,000 shares of the Company’s Series F Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series F Preferred Stock ”), and 100,000 shares of the Company’s Series G Convertible Redeemable Preferred Stock, par value $0.0001 per share (the “ Series G Preferred Stock ,” and together with the Series F Preferred Stock, the “ Preferred Stock ”), at an offering price of $9.50 per share, representing a 5% original issue discount (“ OID ”) to the stated value of $10.00 per share, for gross proceeds of $20 million in the aggregate for the Offering, before the deduction of discounts, fees and offering expenses.”
Kaouthar Lbiati was elected as independent director at Hepion Pharmaceuticals, Inc..
“the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022”
Anand Reddi was elected as independent director at Hepion Pharmaceuticals, Inc..
“the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022”
Tom Adams departed as Director at Hepion Pharmaceuticals, Inc..
“On January 9, 2022, Dr. Tom Adams, a director of Hepion Pharmaceuticals, Inc., passed away.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.